Sonlicromanol for symptoms of primary mitochondrial disease due to the m.3243A>G mutation

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

KHENERFIN is a randomized, double-blind, placebo-controlled Phase 3 trial comparing sonlicromanol to a matched placebo in adults with primary mitochondrial disease caused by the m.3243A>G mutation. Participants are randomly assigned to take sonlicromanol or placebo tablets twice daily for 52 weeks, with a final follow-up visit two weeks after the last dose. Primary outcomes measure changes in fatigue severity and the impact of fatigue on daily life, along with balance control and lower-limb muscle strength; a range of secondary and exploratory outcomes plus safety and tolerability are also collected. Eligibility is confirmed during a screening period (up to 4 weeks) and requires specified heteroplasmy thresholds, chronic fatigue, and the ability to complete the 5x sit-to-stand test.

Why it matters

Who can join: the full rules

Inclusion criteria

1. Signed Informed Consent
2. Males and females aged ≥18 years with a multi-system primary mitochondrial disease.
3. A confirmed mitochondrial DNA tRNALeu(UUR) m.3243A\>G mutation (m.3243A\>G PMD) plus an age adjusted heteroplasmy percentage ≥ 20% in white blood cells \[=blood heteroplasmy/0.977(age+12)\]. Or in urine (urinary epithelial cells), or buccal smear or skeletal muscle (results (obtained per local guidance) ≥ 20% must be available prior to the subject being randomized).
4. Presence of chronic fatigue (not attributable to other etiologies than PMD):

   1. Patient self-reported chronic fatigue for at least 3 months prior to the Screening Visit and recorded in the clinical patient files; AND
   2. Presence of fatigue (raw total score \>22), assessed by Neuro-QoL SFv1-F at Screening.
5. Presence of mitochondrial myopathy defined as:

5xSST at Screening and Baseline should be ≥ 11 seconds and participant must demonstrate the ability to complete the test at baseline (i.e., complete the test within 30 seconds).

6\. Other Inclusion criteria per protocol.

Exclusion criteria

1. Treatment with any IMP within 3 months (or 5 times the half-life of the IMP, whichever is longer) prior to screening or plans to use an IMP (other than the study intervention) during the study.
2. Bone deformities, motor abnormalities or chronic ulcers that in the opinion of the PI may interfere with and/or confound the interpretation of the subject's performance during the 5 times sit to stand test (5XSST).
3. Surgery of gastrointestinal tract that might interfere with drug absorption. Or severe GI dysmotility, chronic vomiting, diarrhea, bouts of pseudo-obstruction which will impair appropriate IMP absorption in the opinion of the investigator.
4. Clinically significant respiratory disease and/or cardiac disease (medical history or current clinical findings) in the opinion of the investigator.
5. Prior interventional cardiac procedure (e.g., cardiac catheterization, angioplasty/percutaneous coronary intervention, balloon valvuloplasty, etc.) within 3 months prior to screening.
6. Structural heart disease based on cardiac MRI or Echocardiography (e.g., clinically significant valve disease; i.e., aortic or mitral valve stenosis or regurgitation) and / or Left ventricular dysfunction (LVEF \<52% in men and \< 54% in women) and / or congestive cardiac failure (more severe than grade II) and / or Maximum left-ventricular septal or posterior wall thickness \> 15 mm and / or Evidence of active myocardial ischaemia, ECG evidence and / or recent history of myocardial infarction (\< 6-months) and / or coronary angioplasty / coronary bypass surgery (\< 12 months).
7. Family history of unexplained/uninvestigated syncope or congenital long and short QT syndrome or sudden death (under the age of 60) and / or Abnormal QTcF interval \[QTcF \> 450 msec (men) or QTcF \> 470 msec (women) = abnormally long QTcF or QTcF \< QT \< 320ms = abnormally short QtcF\] and / or Intermittent or persistent WPW (pre-excitation) syndrome on ECG \[ie: abnormally wide QRS \> 120ms with slurred up-stroke ('delta' wave) and PR-interval \< 120ms\] and / or ECG evidence of atrial fibrillation (permanent, persistent or paroxysmal) and / or

   High grade AV Block \[2nd-degree AV block Type II (ie: 2:1) or complete AV block (3rd degree) or intermittent conduction system abnormalities with the exception of any of the following:
   * 1st degree atrioventricular (AV)-block
   * 2nd degree AV-block Type 1 (Mobitz Type 1 / Wenckebach type)
   * Right bundle branch block.
8. History of acute heart failure (within the last 3 months).
9. Higher degree of AV-blocks (AVB II° or III°).
10. Other exclusion criteria per protocol

Where it's running

• The University of Texas Health Science Center at Houston
  Houston, Texas, United States Recruiting
• Rigshospitalet, University of Copenhagen
  Kopenhagen, Region Sjælland, Denmark Recruiting
• Groupe Hospitalier Pitie-Salpetriere - Charles-Foix Clinical Investigation Center Paris-Est
  Paris, Paris, France Recruiting
• Klinikum der Universität München Friedrich-Baur-Institut
  München, Germany Recruiting
• Fondazione IRCCS Istituto Neurologico Carlo Besta
  Milan, Italy Recruiting
• Radboud University Medical Center
  Nijmegen, Gelderland, Netherlands Recruiting

Study contacts

• Study coordinator: Jasper Levink, MSc.
• Email: Khenerfin@khondrion.com
• Phone: +31 24 7635000

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Metabolic and Functional Study of γδ T Cells in Critically Ill Patients

  Researchers will look at how γδ T cells behave in severely ill patients, including those with sepsis, to see how their metabolism and function change.

  Recruiting Union Hospital, Tongji Medical College, Huazhong University of Science and Technology · Wuhan, Outside of the US · NCT07680816

• Open-label extension to test KL1333 long-term safety and benefit for primary mitochondrial disease

  This extension study will see if KL1333 can be safely used long-term and whether it helps reduce fatigue and improve daily living in adults with primary mitochondrial disease who previously took KL1333 or placebo.

  Recruiting at 23 sites Phase 2 Pharming Technologies B.V. · Akron, Ohio and 22 other locations · NCT07514338

• One-leg exercise training to improve muscle energy and function in adults with mitochondrial myopathy

  This project tests whether a short program of one-leg high-intensity interval exercise changes muscle energy production and molecular signals in adults with mitochondrial myopathy compared with healthy adults.

  Recruiting University of Copenhagen · Copenhagen · NCT07450690

• Using transcriptomic analysis to diagnose mitochondrial diseases

  This study is testing a new way to diagnose mitochondrial diseases by looking at gene activity in patients' cells to help those who haven't been diagnosed yet.

  Recruiting at 2 sites Centre Hospitalier Universitaire de Nice · Nice, Alpes-maritimes and 1 other locations · NCT06621732

• Observing the natural history of mitochondrial diseases

  This study is tracking 400 people with mitochondrial diseases and 100 healthy individuals over 10 years to see how the disease affects them and to help improve future diagnosis and treatment.

  Recruiting Neuroscience Research Australia · Randwick, New South Wales · NCT06504433

• Transplantation of MNV-201 for treating Pearson Syndrome in children

  This study is testing a new cell therapy called MNV-201 to see if it can help children with Pearson Syndrome feel better and manage their symptoms.

  Recruiting Phase 2 Minovia Therapeutics Ltd. · Ramat Gan, Israel · NCT06017869

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.